NCT04850209

Brief Summary

In this study, effects of oral and written education, WeChat education plus oral and written education on Helicobacter pylori eradication will be compared in a randomized way.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
438

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 7, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 20, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

July 23, 2021

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 10, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 10, 2022

Completed
Last Updated

January 31, 2023

Status Verified

January 1, 2023

Enrollment Period

1 year

First QC Date

April 7, 2021

Last Update Submit

January 28, 2023

Conditions

Keywords

helicobacter pylorieradicationpatient educationWechat group

Outcome Measures

Primary Outcomes (1)

  • eradication rate in each group

    Six weeks after completion of treatment,number of patients get H.pylori eradicated supported by negative 13C-UBT results will be investigated by an independent researcher.Then eradication rate in each group will be calculated by using intention-to-treat analysis and per-protocol analysis.

    2 months

Secondary Outcomes (1)

  • prevalence of adverse events

    14 days

Other Outcomes (1)

  • compliance of patients in the two groups

    14 days

Study Arms (2)

Control group

OTHER

Patients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg , amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education

Other: oral and written education

Wechat group

EXPERIMENTAL

Patients in this group will receive clarithromycin based bismuth-containing quadruple therapy, Vonoprazan fumarate 20 mg, colloidal bismuth pectin capsule 200 mg ,amoxicillin 1000 mg and clarithromycin 500 mg, twice daily, 14 days.Patients will receive oral and written education. And patients will be invited into a Wechat group to obtain interactive education through question and answer,which is provided by medical professionals.

Other: oral and written educationOther: Wechat group

Interventions

oral and written education

Control groupWechat group

Wechat group: oral and written education plus Wechat group based interactive education provided by medical professional

Wechat group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • aged between 18 and 75 years old;
  • H. pylori infection confirmed by any two positive outcomes of rapid urease test (RUT), 13C-urea breath test (UBT) or histopathology.

You may not qualify if:

  • previous therapy for H. pylori;
  • with significant underlying disease (e.g. decompensated liver cirrhosis, renal failure or malignant tumors) that may interfere the study;
  • history of gastric surgery,
  • pregnancy or lactation;
  • the use of PPI or antibiotics during the 4 weeks prior to enrolment;
  • previous history of allergic reactions to any of the medications used in this protocol;
  • unable to use smartphone and wechat
  • unwilling or incapable to provide informed consents.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Qilu hosipital

Jinan, Shandong, 257000, China

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The interventions are blind to follow-up personnel who collect and analyze compliance and the incidence of adverse events. The interventions are also blind to the UBT personnel.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: There are two randomized parallel groups in this study, control group and Wechat group.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Director of gastroenterology department of Qilu hospital

Study Record Dates

First Submitted

April 7, 2021

First Posted

April 20, 2021

Study Start

July 23, 2021

Primary Completion

August 10, 2022

Study Completion

September 10, 2022

Last Updated

January 31, 2023

Record last verified: 2023-01

Locations